Citable filing context

BSX filing events and research context

Server-rendered

BSX's research view summarizes recent SEC filing context, starting with mda_quarterly from May 1, 2026.

BSX filing events and research context
FiledItemContext
May 1, 2026mda_quarterlyBoston Scientific reported first-quarter 2026 net sales of $5.2 billion, an 11.6% increase, with 9.4% organic growth. Reported net income rose to $1.34 billion, bolstered by higher sales and a $384 million discrete tax benefit. The Cardiovascular segment led performance with 13.5% growth, driven by the Farapulse Pulsed Field Ablation System, WATCHMAN Left Atrial Appendage Closure Devices, and AGENT Drug-Coated Balloons, despite increased competition and a deceleration in WATCHMAN procedures. Neuromodulation grew 17.4%, led by the Intracept Intraosseous Nerve Ablation and Nalu Peripheral Nerve Stimulation systems. In contrast, Urology growth was constrained to 2.1% by volume-based procurement in China and sacral neuromodulation commercial disruptions. Gross margin improved to 69.4% due to a higher-margin product mix. A significant strategic focus is the $14.5 billion acquisition of Penumbra, which is currently subject to an FTC Second Request. The company maintains a strong liquidity position with $1.45 billion in cash and a 1.87x leverage ratio, well within its 4.25x covenant. Management remains cautious regarding macroeconomic risks, specifically global trade policy uncertainty, tariff volatility, and potential supply chain disruptions.
Feb 17, 2026businessBoston Scientific operates in the highly competitive medical device industry, where growth depends on rapid innovation in AI, machine learning, robotics, and navigation technologies. The company is navigating a structural shift in healthcare as procedures migrate from inpatient settings to outpatient and ambulatory surgical centers. International markets account for 36% of net sales, though growth in these regions is tempered by price-driven government tenders and stringent local regulatory requirements. Financially, the company manages $11.436 billion in debt and is executing a 2023 Restructuring Plan aimed at reducing annual pre-tax expenses by $350 million to $400 million. Key operational risks include supply chain dependencies on single-source vendors, evolving PFAS regulations, and ethylene oxide sterilization constraints. Regulatory headwinds persist via the FDA and the EU’s Medical Device Regulation (MDR). Additionally, the company faces significant exposure to intellectual property litigation and product liability claims. Cybersecurity remains a critical concern due to the complexity of integrated IT/OT systems and strict global data privacy laws, including GDPR and China's PIPL. Success is further contingent on obtaining favorable reimbursement from third-party payers and providing robust health economic evidence to support product procurement.
Feb 17, 2026mdaBoston Scientific reported 2025 net sales of $20.07 billion, a 19.9% increase over 2024, with organic growth of 15.8%. This growth was primarily driven by the Electrophysiology business, specifically the U.S. launch and rapid adoption of the Farapulse Pulsed Field Ablation System. Other significant contributors included WATCHMAN LAAC devices and AGENT drug-coated balloons in the Cardiovascular segment, the Axonics acquisition in Urology, and the Intracept system in Neuromodulation. Expansion in China further bolstered emerging market performance. Conversely, the company discontinued worldwide sales of the ACURATE Neo2 and ACURATE Prime Aortic Valve Systems, resulting in inventory charges and a strategic reallocation of resources. Financial headwinds include cumulative EU MDR implementation costs of $464 million and a global restructuring program estimated to cost between $700 million and $800 million. Management identified material risks regarding U.S. and Chinese tariffs, inflationary pressures, and geopolitical tensions. To sustain its pipeline, R&D expenses rose 27% to $2.05 billion in 2025. Additionally, the company recorded a $194 million litigation charge related to a legacy IP matter. Gross profit margin remained stable at 69.0%, supported by higher-margin product sales.

Source: SEC EDGAR filing text and events; period May 1, 2026; filed May 1, 2026.

Continue research

Keep researching BSX

Follow same-sector companies and source explainers connected to the research view.

Browse Health Care

Related tickers

LLY
Lilly (Eli)
$1.02T
Health Care
Open company page →
JNJ
Johnson & Johnson
$558.88B
Health Care
Open company page →
ABBV
AbbVie
$393.91B
Health Care
Open company page →
UNH
UnitedHealth Group
$369.32B
Health Care
Open company page →
MRK
Merck & Co.
$295.00B
Health Care
Open company page →
AZN
ASTRAZENECA PLC
$281.75B
Health Care
Open company page →

Related explainers

Understanding 8-K filings

A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.

Read explainer →
Reading a 10-Q

A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.

Read explainer →
S-1 and the IPO prospectus

A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.

Read explainer →
Reading an SEC 10-K

A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.

Read explainer →